A B S T R A C T Exogenous arachidonate addition to intact platelets, in the absence or the presence of blood vessel microsomes, results in the production of thromboxane B2 (the stable degradation product of thromboxane A2) only. Prostaglandin (PG) endoperoxides are released from intact platelets only when thromboxane synthetase is inhibited. Thus, addition of exogenous arachidonate to imidazole-pretreated platelets in the presence of bovine aorta microsomes (source of prostacyclin synthetase) results predominantly in the synthesis of 6-keto-PGF,a (the stable degradation product of prostacyclin). Strips of intact aorta were removed from aspirin-treated rabbits, thus the isolated blood vessels were unable to convert endogenous or exogenous arachidonate to prostacyclin. Human platelets, with ['4C]arachidonate-labeled phospholipids, adhered to the blood vessel segments and released some thromboxane B2. The subsequent addition of thrombin facilitated the release of endogenous arachidonate and thromboxane, but no labeled 6-keto-PGF,, was detectable. There is therefore no direct chemical evidence of PG-endoperoxide release from human platelets during either aggregation or adhesion, which therefore precludes the possibility that blood vessels use platelet PG-endoperoxide for prostacyclin synthesis. Imidazole inhibited the thromboxane synthetase in the labeled platelets, and thereafter thrombin stimulation resulted in the release of platelet-derived, labeled PG-endoperoxides that were converted to labeled prostacyclin by the vascular prostacyclin synthetase. The latter result suggests a potential antithrombotic therapeutic benefit might be achieved using an effective thromboxane synthetase inhibitor.
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INTRODUCTION
Isolated intact blood vessels, arterial rings, or vascular homogenates have been demonstrated to convert small Received for publication 10 November 1978 and in revised form 1 December 1978. amounts of arachidonic acid into prostacyclin (PGI2)' (1-3). However, vascular tissue quantitatively converts prostaglandin (PG) endoperoxides into PGI2 (4, 5) . In addition, indomethacin-treated blood vessel segments, stirred with platelet-rich plasma, prevent aggregation (2, 6) . These data led to a hypothesis that advocates that endoperoxides are released from platelets during aggregation or adhesion and are used by the blood vessels to synthesize prostacyclin (2, 7, 8) . A homeostatic balance exists between thromboxane (the platelet-derived blood vessel contractor and platelet aggregator) and PGI2 (the vasodilator, antithrombotic substance produced by blood vessels). If plateletderived endoperoxides are in fact used by vasculature, then preferential synthesis of PGI2 over thromboxane would be anticipated. This hypothesis was supported by the observation that combination of lysed human platelets with lysed rat aortic smooth muscle cells increased the production of PGI2 from arachidonate, whereas platelets alone did not produce PGI2 (9) . The current experiments were designed to provide direct chemical evidence regarding the ultimate fate of PGendoperoxides generated in intact platelets during aggregation or adhesion.
METHODS
[I4C]PGH2. This was enzymatically synthesized and purified with acetone-pentane powder of sheep seminal vesicle microsomes as previously described (10, 11) .
15-hydroperoxy-arachidonic acid. As an in vitro PGI2 synthetase inhibitor (12) , this was synthesized enzymatically with soybean lipoxygenase and purified as previously described (13) . PG standards. PGE2, D2, A2, 6-keto-PGF,,,, and thromboxane B2 were kindly supplied by The Upjohn Co., Kalamazoo, Mich.
Bovine aorta microsomes (BAM). These were employed as the source of PGI2 synthetase and were prepared from freshly dissected vessels. The arteries were minced, homogenized, and centrifuged for 10 min at 10,000 g. The supernate was centrifuged for 60 min at 100,000g. The pellet was resuspended in 50 mM phosphate buffer (pH 7.4) to yield a 4 mg/ml protein concentration and stored at -700C. Washed platelet preparation. Washed human platelet suspensions were prepared as previously described (14) .
Platelet phospholipid labeling technique. Human blood was withdrawn into a syringe containing 1/13 vol of 77 mM EDTA. The erythrocytes were removed by centrifugation for 10 min at 120 g and the supernate was centrifuged at 4,000 g for 6 min. The platelets were resuspended in 2/3 vol of albumin-phosphate buffer (33 mM, pH 6.5) containing 1 mg/ ml glucose, 6.6 mg/ml NaCl, and 5 mg/ml fatty acid poor bovine serum albumin.
[14C]arachidonic acid (2 x 106cpm), obtained from Amersham Corp., Arlington Heights, Ill. (55 mC/mmol), was dissolved in 100 ,lI of Tris buffer (100 mM, pH 9.0) and added to the platelet suspension that was incubated for 30 min at 370C. The labeled platelets were centrifuged at 2,000 RPM for 5 min and resuspended in calcium-free Krebs Henseleit media (pH 7.4). Chromatographic analysis of the lipids extracted from these prelabeled platelets indicated that the incorporated radioactivity was primarily in the phosphatidyl choline and phosphatidyl ethanolamine fraction, with only trace amounts of free arachidonate detectable.
Extraction and chromatography. The reaction mixtures were acidified to pH 3.5 with 2 N formic acid aind extracted twice with 2 vol of ethyl acetate. The combined organic extract was dried over anhydrous Na2SO4, concentrated in a stream of N2, and applied together with unlabeled PG standards to silica gel G thin layer chromatography plates (Brinkman Instruments, Inc., Westbury, N. Y.). The solvent system (BDA) employed to demonstrate the presence ofthromboxane B2 was benzene:dioxane:acetic acid (60:30:3). The solvent system (A-9) employed to separate the PGI2 metabolite was the organic phase from ethyl acetate:acetic acid:2,2,4-trimethvl pentane:water (110:20:50:100) (15) . The PG standards were visualized by iodine staining, the radioactive peaks were detected on a Vanguard Scanner (Packard Instrument Co., Downers Grove, Ill.).
RESULTS
Exogenous arachidonate metabolism by intact platelets and blood vessel microsomes. BAM were employed as a source of PGI2 synthetase to rapidly convert any available endoperoxide into PGI2. PGI2 decays to the stable metabolite 6-keto-PGF,,, which is readily detected on thin layer chromatograms.
Washed human platelet suspensions rapidly converted [14C]arachidonic acid into thromboxane B2 (Fig. IA) . There was no detectable shift in exogenous arachidonate metabolism when the intact platelets were combined with the blood vessel microsomes (Fig.  IB) . These experiments indicate that the aggregating platelets were not releasing endoperoxides. Preincubation of the platelet suspensions with the thromboxane synthetase inhibitor imidazole (16, 17) , before the addition of exogenous arachidonate, abolished the thromboxane B2 formation and resulted in the appearance of PGE2 and a trace of PGD2 (Fig. ID) . The PGE2 and PGD2 formation could have resulted either from the system, thromboxane B2 (TB) comigrates with PGE2 (E). The chromatographs shown were separated in the BDA solvent system (i.e., A-E) except for F which was separated in the A-9 system. All radiochromatograms were evaluated at the same gain setting on the Vanguard Scaanner. The appropriate zones from the thin layer plate were scrapped, eluted, and counted, thus the TB Only when the vascular PGI2 synthetase was inhibited with the hydroperoxy fatty acid did the platelets convert endoperoxide to thromboxane. Thus, in mixing experiments of intact platelets and blood vessel microsomes, 6-keto-PGFi,a was the primary product formed from exogenous endoperoxide. In contrast, thromboxane B2 was the primary product derived from intrinsic platelet PGI2 interactions between prelabeled platelets and intact blood vessels. Vascular microsomes lack membrane barriers that might prevent the penetration of the endoperoxide to the PGI2 synthetase. Furthermore, the above experiments analyzed the possibility of endoperoxide release during aggregation (i.e., platelet-toplatelet interaction). A different situation may occur during the adhesion reaction, i.e., platelet-to-blood vessel interaction.
Rabbit aorta were removed from animals (n = 4) pretreated for 2 Fig. 2A) . Addition of rabbit aorta segments was followed by a rapid decrease in the opacity of the suspension of the labeled platelets, and extraction of the media indicated some thromboxane B2 formation and arachidonate (including hydroxy fatty acids) release (Fig. 2B) . The aorta segments were removed after incubation with the platelets and were rinsed three times, blotted, and solubilized (Soluene, New England Nuclear, Boston, Mass.) for scintillation counting. 30% (61,000 cpm) of the radioactivity originally present in the labeled platelets was now tightly associated with the blood vessels, thereby indicating platelet-to-blood vessel adhesion.
Thrombin (Fig. 2C) or the calcium ionophore-A-23187 (not shown) added 5 min after the labeled platelets and blood vessels were mixed facilitated the plate- The rabbit aorta (RA) segments were removed from aspirintreated (250 mg/kg orally 2 h before removal) rabbits, cleaned free of adventitia, and sectioned. Four vessel segments (total wet weight of 60-100 mg) were added to 2 ml of the prelabeled platelets (described in Methods). Thrombin (5 U) was used to stimulate platelet phospholipase activity. The release of radioactivity varied with the intensity of the response, thereby requiring different scanner gains. To quantitate the responses, the radioactive peaks were scrapped, eluted, and counted, and the numbers are indicated on the figure with the appropriate peak. The arachidonic acid (AA) present on scans B, C, and D were so high that the gain of the scanner was reduced by a factor of 3 (indicated by x3). This representative experiment was repeated four times with comparable results.
let adhesion to the blood vessels (vascular radioactivity, 95,000 cpm), resulted in a pronounced release of [14C]arachidonate and [14C]thromboxane, but no labeled 6-keto-PGF1,, was detected (Fig. 2C) . Thrombin has recently been shown to facilitate platelet adhesion to endothelial and vascular smooth muscle cells (19) . Only when imidazole pretreatment blocked the platelet thromboxane synthetase was there any labeled substrate available for vascular (platelet adhesion was -50%, i.e., 104,000 cpm) PGI2 synthesis (Fig. 2D ).
Comparable results were achieved when either aspirintreated rat aorta or bovine coronary artery were employed instead of rabbit aorta. (Figs. 1F and 2D ), ultimately resulting in PGI2 production and inhibition of local platelet aggregation. Platelet membrane is reported to remain intact after adhesion to vascular tissue (22) normally precluding an opportunity for endoperoxide release from platelets. These results reinforce the potential therapeutic benefit that would be achieved with a clinically effective thromboxane synthetase inhibitor.
DISCUSSION
Finally, some controversy exists about the ability of PG-endoperoxides to penetrate cell membranes to the PGI2 synthetase. Intact cultured endothelial cells have been demonstrated to convert exogenous PGH2 into PGI2 (23, 24) , whereas isolated perfused rabbit hearts do not (25) . In agreement with the latter observation, PGI2 synthesis was stimulated by treatment of a perfused rabbit mesenteric vascular bed with exogenous arachidonate or angiotensin II (which releases endogenous arachidonate), but not by exogenous PGH2 (26) . Furthermore, when the endothelium of the mesenteric vasculature was completely denuded by hypotonic shock, the arachidonate and the angiotensin still produced comparable levels of PGI2, indicating the effectiveness of the subendothelial vascular smooth muscle in synthesizing PGI2. The lack of evidence of PG endoperoxide release from intact platelets (at levels that we can detect, i.e., '1% total radioactivity) coupled with the apparent inability of numerous intact vascular tissues to convert PGH2 into PGI2 therefore seems to compromise the hypothesis that blood vessels use platelet PG endoperoxides for PGI2 synthesis.
